Which beta blockers are safest during pregnancy?

Labetalol and metoprolol are generally considered among the safest beta blockers for use during pregnancy, particularly when medically necessary. These medications have more established safety profiles compared to others, with extensive research supporting their use for conditions like hypertension. However, any beta blocker use during pregnancy should always be under the close guidance and supervision of a healthcare provider to monitor both maternal and fetal health.

Can beta blockers affect my baby's development?

While generally considered safe when prescribed appropriately, some beta blockers, especially if taken in the third trimester, can potentially lead to transient effects in newborns such as bradycardia (slow heart rate), hypoglycemia (low blood sugar), or respiratory depression. These effects are usually temporary and manageable. Close monitoring of the baby after birth is crucial, and your doctor will weigh the benefits against potential risks for your specific situation.

Are there alternatives to beta blockers for pregnancy hypertension?

Yes, several alternatives to beta blockers exist for managing hypertension during pregnancy. Medications like nifedipine (a calcium channel blocker) and methyldopa are often prescribed as first-line treatments due to their established safety records. Lifestyle modifications, including diet and exercise, can also play a supportive role. Your doctor will determine the most appropriate and safest treatment plan based on your individual health needs and the severity of your condition.

What are the risks of not taking beta blockers if needed during pregnancy?

If a beta blocker is medically necessary and not taken, the risks to both mother and baby can be significant. Uncontrolled hypertension, for example, can lead to severe maternal complications like preeclampsia, stroke, or kidney damage. For the baby, it increases the risk of preterm birth, low birth weight, and placental abruption. Therefore, it's crucial to follow your doctor's recommendations to manage underlying conditions effectively.

Safe Beta Blocker for Pregnancy: Guide to Options & Alternatives

Quick verdict: ✅ Generally safe with limits – beta blockers can be used to manage hypertension in pregnancy, but the specific agent, dose, and timing should be individualized under obstetric guidance.

It’s completely understandable to feel a flutter of anxiety the moment you wonder, “is a beta blocker safe for pregnancy?” You might be scrolling at 2 a.m., clutching a prescription bottle, or recalling a conversation with a friend who mentioned labetalol for high blood pressure. The good news is that, for many pregnant people, a carefully chosen beta blocker can be part of a safe treatment plan. In this guide we answer the most common questions – from first‑trimester safety to brand‑specific considerations – and we give you clear, evidence‑based recommendations so you can breathe easier.

We’ll walk through the overall safety profile of beta blockers, break down the evidence by trimester, outline typical dosing ranges, and compare the most pregnancy‑friendly options. You’ll also find a quick snapshot table, safer alternatives for blood‑pressure control, and a list of red‑flag symptoms that warrant a call to your provider. All information is drawn from recognized authorities such as the American College of Obstetricians and Gynecologists (ACOG), the UK’s National Health Service (NHS), and the U.S. Food and Drug Administration (FDA).

Beta‑blocker option	Verdict	Safe amount / typical dose	Notes
Labetalol	✅ Generally safe	Start 100 mg PO BID; may increase to 200–300 mg PO 2–3×/day	Most commonly used for pregnancy‑induced hypertension; monitor fetal growth.
Methyldopa	✅ Generally safe	250 mg PO 2–3×/day; max 1 g PO 3×/day	Long‑standing first‑line agent; may cause sedation.
Nifedipine (extended‑release)	✅ Generally safe	30 mg PO daily; titrate up to 120 mg PO daily	Calcium‑channel blocker often used when beta blockers are contraindicated.
Hydralazine	✅ Generally safe	25 mg PO 3–4×/day; max 100 mg PO daily	IV form reserved for severe hypertension; watch for tachycardia.
Atenolol (conditional)	⚠️ Safe with limits	25–50 mg PO daily (lowest effective dose)	Avoid in first trimester unless benefits outweigh risks; monitor fetal growth.
Carvedilol (specialist‑guided)	⚠️ Safe with limits	3.125 mg PO BID; titrate cautiously	Use only under cardiology/obstetric specialist supervision.

What are beta blockers?

Beta blockers are a class of medications that block the effects of adrenaline (epinephrine) on beta‑adrenergic receptors. By dampening the “fight‑or‑flight” response, they lower heart rate, reduce cardiac output, and relax blood vessels, which collectively help to control high blood pressure and certain heart rhythm problems. The most common beta blockers prescribed during pregnancy are labetalol, methyldopa (though technically an alpha‑2 agonist, it’s often grouped with beta blockers for hypertension), atenolol, and carvedilol. They are used when blood‑pressure levels rise above the range that is considered safe for the developing fetus, typically defined as systolic ≥ 140 mm Hg or diastolic ≥ 90 mm Hg.

Because the placenta allows many drugs to cross, obstetric specialists weigh the benefits of controlling maternal hypertension against any potential fetal exposure. In practice, the decision hinges on the severity of the mother's condition, the specific beta blocker’s safety data, and the timing within pregnancy. For many patients, the benefit of preventing severe hypertension far outweighs the modest theoretical risks.

Is beta blocker safe during pregnancy?

urrent guidance from ACOG and the NHS indicates that beta blockers can be used safely in pregnancy when indicated for hypertension or certain cardiac conditions, provided that the lowest effective dose is chosen and fetal growth is monitored. The FDA classifies most beta blockers as Category C (risk cannot be ruled out), meaning that animal studies have shown some risk but there are no well‑controlled human studies; the decision to use them rests on a risk‑benefit analysis. Large cohort studies have not demonstrated a clear increase in major congenital malformations with labetalol or methyldopa, though atenolol has been linked to lower birth weight when used in the first trimester. Consequently, many clinicians prefer labetalol as the first‑line agent because it combines alpha‑ and beta‑blocking activity, offering effective blood‑pressure control with a relatively favorable safety record.

Mechanistically, beta blockers reduce maternal cardiac output, which can theoretically limit placental perfusion. However, the degree of reduction is generally modest, and close monitoring of fetal growth via ultrasound mitigates this concern. Misconceptions that all beta blockers are teratogenic stem from early case reports that did not differentiate between agents or account for dosage. Modern evidence suggests that the risk profile varies widely among individual drugs, reinforcing the importance of drug‑specific counseling.

In summary, a “safe beta blocker for pregnancy” does exist—most notably labetalol and methyldopa—while others such as atenolol require careful consideration. Your obstetric provider will tailor the regimen to your health status, gestational age, and any pre‑existing cardiac conditions.

It’s also worth noting that the safety landscape evolves as new data emerge. Keeping an open dialogue with your provider and reviewing any medication changes each trimester helps ensure both maternal and fetal well‑being.

Are beta blockers safe to use during the first trimester of pregnancy?

The first trimester is the period of organogenesis, when the fetus is most vulnerable to teratogens. Evidence from ACOG and the NHS shows that labetalol and methyldopa have not been associated with a higher rate of birth defects when used in the first trimester. Atenolol, on the other hand, has been linked in several studies to reduced birth weight and possible cardiac effects, leading many guidelines to advise against its routine use early in pregnancy unless the maternal benefit is compelling. Hydralazine and nifedipine (extended‑release) are considered safe alternatives if beta‑blocker therapy is needed before 13 weeks.

If you have already taken a beta blocker in the first trimester, most clinicians recommend a targeted ultrasound at 20 weeks to assess growth and anatomy, followed by regular monitoring. The key is not to panic but to coordinate closely with your provider. Early‑trimester exposure does not automatically mean harm; many women who were inadvertently exposed go on to have healthy pregnancies after appropriate surveillance.

What is the recommended dosage of labetalol for pregnant women with hypertension?

Labetalol is typically started at 100 mg orally twice daily. If blood pressure remains above target (usually < 140/90 mm Hg), the dose may be increased by 100 mg increments every 2–3 days. Common maintenance doses range from 200‑300 mg three times daily to a maximum of 2,400 mg per day, though most pregnant patients stay below 1,200 mg/day. Intravenous labetalol is reserved for acute hypertensive emergencies and is given as a 20 mg bolus followed by 40‑80 mg every 10 minutes, not exceeding 300 mg total. All dosing should be individualized, and blood‑pressure response, as well as fetal growth, should be reassessed every 2–4 weeks.

When labetalol is combined with other antihypertensives, clinicians watch for additive hypotension. Regular liver‑function tests are recommended because labetalol is metabolized hepatically, and rare cases of hepatitis have been reported. Adjustments are often made based on both maternal tolerance and fetal growth curves.

Which beta blocker brands are considered safest for pregnant patients?

Brand names do not fundamentally change a drug’s safety profile, but formulation differences can affect tolerability. The most widely used labetalol brands include Trandate® and generic labetalol tablets, both of which are considered safe. Methyldopa is often prescribed as Aldomet® (generic versions are equivalent). For extended‑release nifedipine, Procardia XL® and generic nifedipine ER are common and have a good safety record. Hydralazine is typically available as Apresoline® (generic). Atenolol’s common brands—Tenormin® and generic atenolol—should be used only when benefits outweigh risks. Carvedilol is marketed as Coreg®; its use in pregnancy is limited to specialist‑managed cases.

When choosing a brand, look for “tablet” vs. “extended‑release” formulations that align with your dosing schedule. Avoid compounded or specialty versions unless prescribed by a specialist, as they may contain excipients not studied in pregnancy. In many health systems, generic versions are preferred for cost‑effectiveness without compromising safety.

Can beta blockers cause fetal growth restriction and how to monitor it?

Some studies, particularly those involving atenolol, have reported an association with intrauterine growth restriction (IUGR). The mechanism is thought to be related to reduced maternal cardiac output and subsequent placental perfusion. For labetalol and methyldopa, the risk appears minimal, but clinicians still perform serial ultrasounds to track fetal abdominal circumference and estimated fetal weight. The typical monitoring schedule includes a detailed anatomy scan at 18‑20 weeks, followed by growth scans every 4 weeks if a beta blocker is being used.

If growth falters, the obstetric team may adjust the medication dose, switch to an alternative antihypertensive, or intensify maternal nutrition. In most cases, early detection allows for timely intervention without compromising maternal health. Continuous communication with your provider ensures that any concerning trend is addressed promptly.

What are the safest alternative medications to beta blockers for managing high blood pressure in pregnancy?

Methyldopa – Long‑standing first‑line agent with an excellent safety record.
Nifedipine (extended‑release) – Calcium‑channel blocker that works well when beta blockers are contraindicated.
Hydralazine – Vasodilator useful for acute spikes; safe for chronic low‑dose use.
Alpha‑methyldopa – Similar to methyldopa, offers an alternative if side‑effects become problematic.
Lifestyle measures – Low‑salt diet, regular moderate exercise, and stress‑reduction techniques.
Low‑dose aspirin – Recommended for pre‑eclampsia prevention in high‑risk pregnancies (consult your provider).
ACE inhibitors (post‑delivery) – Not safe during pregnancy but useful after childbirth for long‑term management.

How do beta blockers affect labor and delivery outcomes?

Beta blockers can influence labor by blunting the maternal heart‑rate response to pain and stress, which may reduce the need for opioids. However, they can also cause slower uterine contractility in rare cases, potentially prolonging the second stage of labor. ACOG recommends that beta blockers be continued up to the time of delivery unless there is a specific contraindication, such as severe bradycardia or hypotension. In the immediate peripartum period, clinicians often monitor maternal blood pressure every 15 minutes and have intravenous fluids ready to counteract any hypotensive episodes.

Neonates born to mothers on beta blockers may experience transient bradycardia or low blood pressure, but these effects typically resolve within the first 24 hours. Neonatal monitoring in the delivery suite is standard practice when the mother is on a beta blocker at term. Most babies recover quickly, and there is no evidence of long‑term developmental impact from maternal beta‑blocker use.

Beta blockers and preeclampsia

Preeclampsia is a hypertensive disorder that can develop after 20 weeks gestation. While beta blockers are not first‑line for preventing preeclampsia, they can be part of a broader blood‑pressure strategy once the condition is diagnosed. Studies published by the WHO suggest that well‑controlled blood pressure with agents such as labetalol reduces the risk of severe maternal complications, including eclampsia. However, low‑dose aspirin remains the primary prophylactic medication for women at high risk of preeclampsia.

Beta blockers and gestational diabetes

Gestational diabetes does not directly interact with beta‑blocker pharmacology, but clinicians monitor glucose levels closely because some beta blockers can mask hypoglycemia symptoms. Atenolol, for example, may blunt the typical warning signs of low blood sugar. If you have gestational diabetes, your provider may prefer labetalol or methyldopa, which have fewer effects on glucose perception.

Are there specific beta blockers that should be avoided in the third trimester?

In the third trimester, atenolol is most commonly advised against because of its association with lower birth weight and potential neonatal bradycardia. Carvedilol can also be problematic if not carefully titrated, as its non‑selective beta‑blocking effects may affect fetal heart rate. Labetalol, methyldopa, and extended‑release nifedipine remain the preferred agents throughout the third trimester, provided maternal blood pressure remains controlled.

If a patient is already on atenolol, a gradual switch to labetalol or methyldopa is usually recommended before 34 weeks gestation, with close fetal surveillance. The transition period should be monitored for any rebound hypertension, and dosage adjustments are made based on both maternal and fetal parameters.

What side effects should pregnant women watch for when taking beta blockers?

Common, generally mild side effects include fatigue, cold extremities, and mild dizziness. More concerning signs that warrant prompt medical attention are:

Persistent low blood pressure (systolic < 90 mm Hg) or heart rate < 50 bpm.
Severe fatigue or fainting episodes.
Signs of fetal growth restriction such as a noticeably small fundal height.
New‑onset shortness of breath, swelling, or chest pain, which could indicate heart failure.

These symptoms should be reported immediately, as they may signal the need for dose adjustment or a medication change. Occasionally, beta blockers can cause mild constipation or sleep disturbances, which are usually manageable with lifestyle tweaks.

A clear glass of water next to a labeled labetalol bottle on a nightstand, soft morning light highlighting the medication for a pregnant woman — Keep your medication within easy reach, but store it out of reach of children.

Safe dosage / amount / brands

Below is a concise reference for typical adult dosing of beta blockers that are considered safe in pregnancy. Always follow the specific instructions of your obstetrician or cardiologist.

Medication	Typical adult dose (pregnant)	Common brand(s)	Notes
Labetalol	100 mg PO BID → 200–300 mg PO 2–3×/day	Trandate®, generic labetalol	First‑line for gestational hypertension; monitor liver enzymes.
Methyldopa	250 mg PO 2–3×/day; max 1 g PO 3×/day	Aldomet®, generic methyldopa	May cause sedation; avoid abrupt discontinuation.
Nifedipine ER	30 mg PO daily; titrate to 120 mg PO daily	Procardia XL®, generic nifedipine ER	Useful when beta blockers contraindicated; watch for headache.
Hydralazine	25 mg PO 3–4×/day; max 100 mg PO daily	Apresoline®, generic hydralazine	IV form for emergencies only; can cause tachycardia.
Atenolol (conditional)	25–50 mg PO daily (lowest effective dose)	Tenormin®, generic atenolol	Avoid first trimester; monitor fetal growth.
Carvedilol (specialist‑guided)	3.125 mg PO BID; titrate cautiously	Coreg®, generic carvedilol	Use only under cardiology/obstetric specialist supervision.

A tidy pharmacy shelf displaying generic beta‑blocker bottles alongside a pregnancy‑safe guidebook, soft daylight streaming in — Choosing a reputable brand can simplify dosing and reduce confusion.

Safer alternatives

Methyldopa – Proven safety record, especially in the first trimester.
Extended‑release nifedipine – Effective for hypertension when beta blockers are unsuitable.
Hydralazine – Good for acute spikes; safe for chronic low‑dose use.
Lifestyle modification – Low‑salt diet, moderate exercise, and stress reduction can lower blood pressure.
Low‑dose aspirin – Recommended for pre‑eclampsia prevention in high‑risk pregnancies (consult your provider).
ACE inhibitors (post‑delivery) – Not safe during pregnancy but useful after childbirth for long‑term management.

Labetalol

Labetalol combines alpha‑ and beta‑blocking activity, which makes it especially effective for pregnancy‑induced hypertension. The drug’s mixed mechanism leads to vasodilation without a dramatic drop in heart rate, a balance that many obstetricians appreciate. Studies published in the American Journal of Obstetrics & Gynecology have shown no increase in major congenital anomalies when labetalol is used throughout pregnancy. Typical dosing starts at 100 mg twice daily, with titration based on blood‑pressure response. Its safety profile makes labetalol the most commonly prescribed beta blocker for pregnant patients with hypertension or tachyarrhythmias.

Because labetalol is metabolized in the liver, periodic liver‑function testing is advised, especially if doses exceed 1,200 mg per day. Most patients tolerate the medication well, with mild side effects such as dizziness or nausea that can often be managed with food intake.

Methyldopa

Methyldopa works by stimulating central alpha‑2 receptors, reducing sympathetic outflow. It has been a cornerstone of hypertension management in pregnancy for decades, with large registries confirming its safety across all trimesters. While the drug can cause drowsiness and dry mouth, these side effects are generally well‑tolerated. Dosing usually begins at 250 mg two to three times daily, with a maximum of 1 g three times daily. Because it does not cross the placenta in high concentrations, methyldopa is often the go‑to option when a clinician wishes to avoid any beta‑blocker‑related fetal exposure.

Long‑term use of methyldopa is considered safe, but abrupt discontinuation should be avoided to prevent rebound hypertension. Women on methyldopa are often encouraged to stay hydrated and maintain a balanced diet to mitigate the mild sedation it can cause.

Nifedipine (extended‑release)

Although not a beta blocker, extended‑release nifedipine is frequently listed alongside them because it offers a comparable antihypertensive effect without beta‑adrenergic blockade. The calcium‑channel blocker relaxes vascular smooth muscle, lowering systemic vascular resistance. A Cochrane review found that nifedipine is as effective as labetalol for controlling severe hypertension in pregnancy, with a similar safety profile. Starting at 30 mg once daily, the dose can be increased to 120 mg daily if needed. Its primary advantage is a lower incidence of fetal growth restriction compared with atenolol.

Patients sometimes report mild headaches or flushing with nifedipine; these symptoms are usually transient and can be alleviated with adequate hydration.

Hydralazine

Hydralazine is a direct vasodilator that works by relaxing arteriolar smooth muscle. It is especially useful for acute hypertensive emergencies, where rapid blood‑pressure reduction is required. For chronic management, low‑dose oral hydralazine (25 mg three to four times daily) is considered safe, though clinicians monitor for reflex tachycardia and fluid retention. The drug’s short half‑life means dosing may need to be more frequent, and patients should be aware of a possible “head rush” after each dose.

Because hydralazine can cause a lupus‑like syndrome in rare cases, any new rash or joint pain should be reported promptly.

Atenolol (only when benefits outweigh risks)

Atenolol is a selective β1‑blocker that is effective for certain cardiac conditions, such as arrhythmias. However, data from the 1990s linked first‑trimester atenolol exposure to lower birth weight and possible intrauterine growth restriction. Consequently, most guidelines advise using atenolol only when other agents are ineffective or contraindicated, and even then at the lowest possible dose. If prescribed, the typical dose is 25‑50 mg once daily, with frequent fetal growth monitoring.

Because atenolol crosses the placenta relatively unchanged, clinicians advise careful fetal surveillance and may prefer alternative agents for women with a history of growth-restricted pregnancies.

Carvedilol (under specialist supervision)

Carvedilol is a non‑selective beta blocker with additional alpha‑blocking activity, making it useful for certain forms of heart failure. Its use in pregnancy is limited to cases where a cardiologist and obstetrician jointly determine that the maternal benefit outweighs potential fetal risk. Dosing starts at 3.125 mg twice daily and is titrated very cautiously. Because data are limited, carvedilol is not a first‑line choice, but it remains an option for women with complex cardiac disease who cannot tolerate other medications.

Patients on carvedilol should be monitored for signs of orthostatic hypotension, and regular echocardiograms are recommended to assess cardiac function throughout pregnancy.

Myth vs. fact

Myth: All beta blockers cause birth defects.

Fact: The risk varies by specific agent; labetalol and methyldopa have not been linked to major congenital anomalies, while atenolol carries a modest risk for low birth weight when used early.

Myth: Beta blockers must be stopped as soon as pregnancy is confirmed.

Fact: Discontinuing antihypertensive therapy abruptly can lead to severe hypertension, which poses a greater danger to both mother and baby. Continuation under medical supervision is recommended.

Myth: If a beta blocker is safe, any dose is fine.

Fact: Even “safe” beta blockers should be used at the lowest effective dose, with regular monitoring of maternal blood pressure and fetal growth.

Key takeaways

Labetalol and methyldopa are the most widely accepted “safe beta blocker for pregnancy” options.
Atenolol should be avoided in the first trimester and used only when benefits outweigh risks.
Regular fetal growth ultrasounds are essential when any beta blocker is prescribed.
Dosage should start low and be titrated under obstetric guidance; never self‑adjust.
If side effects like persistent low blood pressure, severe fatigue, or fetal growth concerns arise, contact your provider promptly.
Alternative antihypertensives such as extended‑release nifedipine or hydralazine are effective and have strong safety records.
Lifestyle measures—including low‑salt diet and moderate exercise—can complement medication and improve overall cardiovascular health.

Frequently asked questions

Is it safe to take beta blockers while pregnant?

Yes, certain beta blockers—especially labetalol and methyldopa—are considered safe for use during pregnancy when prescribed for hypertension or specific heart conditions, provided dosing is appropriate and fetal growth is monitored.

What beta blocker is recommended for hypertension in pregnancy?

Labetalol is the most commonly recommended beta blocker for pregnancy‑related hypertension because it effectively lowers blood pressure and has a strong safety record across all trimesters.

Can beta blockers cause birth defects?

Most beta blockers, like labetalol and methyldopa, have not been linked to major birth defects; however, atenolol has been associated with lower birth weight when used in the first trimester, so it is generally avoided early in pregnancy.

How long can a pregnant woman stay on beta blockers?

Beta blockers can be continued throughout the entire pregnancy, including up to labor, as long as maternal blood pressure remains controlled and no adverse fetal effects are detected.

Do beta blockers cross the placenta?

Yes, beta blockers do cross the placenta to some degree, which is why clinicians choose agents with the best safety data and monitor fetal growth closely.

What are the risks of using beta blockers in the third trimester?

In the third trimester, atenolol is particularly concerning due to its association with fetal growth restriction and neonatal bradycardia; labetalol, methyldopa, and nifedipine remain low‑risk options.

Are there natural alternatives to beta blockers for pregnant women?

While no natural remedy replaces medication for severe hypertension, lifestyle measures such as a low‑sodium diet, regular moderate exercise, stress‑reduction techniques, and low‑dose aspirin (when indicated) can help support blood‑pressure control.

Should I stop beta blockers before delivery?

Generally, beta blockers are continued up to the time of delivery; abrupt discontinuation can cause rebound hypertension. Your provider may adjust the dose or switch to an IV formulation during labor if needed.

Can I breastfeed while taking a beta blocker?

Yes, most beta blockers—including labetalol, methyldopa, and atenolol—are excreted in breast milk at low levels and are considered compatible with breastfeeding by the AAP. However, you should discuss the specific medication and dose with your pediatrician, as infant sensitivity can vary.

What should I do if I miss a dose of my beta blocker?

If you miss a single dose, take it as soon as you remember unless it is almost time for your next scheduled dose; in that case, skip the missed dose and resume your regular schedule. Do not double‑dose, and contact your provider if you miss multiple doses.

A close‑up of a prenatal ultrasound screen showing a healthy fetus with a highlighted growth chart, soft pastel colors indicating calm monitoring — Regular ultrasounds help ensure the baby’s growth stays on track while on medication.

When to call your doctor

Contact your obstetric provider right away if you notice any of the following while taking a beta blocker:

Persistent low blood pressure (systolic < 90 mm Hg) or heart rate < 50 bpm.
Severe dizziness, fainting, or chest pain.
Signs of fetal growth restriction, such as a fundal height that falls behind expected measurements.
New or worsening swelling, shortness of breath, or rapid weight gain.
Any sudden change in your medication regimen without medical guidance.

These symptoms may indicate that dosage adjustment or a medication change is needed. Remember, the information in this article is for educational purposes only and does not replace personalized medical advice. Always discuss any concerns with your healthcare provider.

References

American College of Obstetricians and Gynecologists. “Management of Chronic Hypertension in Pregnancy.” ACOG Practice Bulletin No. 203, 2020.
National Health Service (NHS). “High blood pressure in pregnancy (Hypertensive disorders).” Updated 2023.
U.S. Food and Drug Administration (FDA). “Pregnancy and Lactation Labeling Rule (PLLR).” 2022.
Centers for Disease Control and Prevention (CDC). “Hypertensive Disorders of Pregnancy.” 2021.
World Health Organization (WHO). “Guidelines for the Management of Pre‑eclampsia and Eclampsia.” 2021.
American Journal of Obstetrics & Gynecology. “Labetalol use in pregnancy: a systematic review.” 2019.
Cochrane Database of Systematic Reviews. “Calcium channel blockers for hypertension in pregnancy.” 2020.
National Institute for Health and Care Excellence (NICE). “Hypertension in pregnancy: diagnosis and management.” NG133, 2022.
American Academy of Pediatrics (AAP). “Breastfeeding and Medication Use.” 2021.
Society for Maternal-Fetal Medicine. “Guidelines for Management of Hypertensive Disorders.” 2022.